U.S. FDA Opposes Otsuka suit, Apotex Can Challenge Benicar Patents
This article was originally published in PharmAsia News
Executive Summary
FDA asks court to dismiss Otsuka’s Abilify suit; Apotex can seek infringement ruling on disclaimed Benicar patent; Apotex damages for omeprazole launch must be recalculated; hedge fund manager Kyle Bass files IPR petitions against Jazz and Shire.
You may also be interested in...
Power Of Proprietary Drug Names To Be Studied By US FDA
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.
Decade In Review: Biopharma's Shifting Legal Landscape
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
US FDA's Decade In Review: From Biosimilars To Real-World Evidence
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
Need a specific report? 1000+ reports available
Buy Reports